Galena Biopharma
GALE, a biopharmaceutical company commercializing and developing
innovative, targeted oncology treatments that address major unmet medical
needs to advance cancer care, today announced the initiation of the Company's
Institutional Review Board (IRB)-approved cancer patient registry study
entitled RELIEF: Rapid Evaluation of Lifestyle, Independence, and Elimination
of breakthrough cancer pain with Freedom from oral discomfort through the use
of Abstral® (fentanyl) Sublingual Tablets. RELIEF is a post-marketing
multicenter trial to assess Abstral for breakthrough cancer pain (BTcP) in
opioid-tolerant cancer patients. Abstral is available to patients and health
care professionals at pharmacies nationwide, and recruitment and enrollment
for the registry trial is underway.
RELIEF is a registry study to be completed by enrolled patients over a thirty
day period while using Abstral for treatment of their breakthrough cancer
pain. Approximately 2,500 patients are expected to enroll in the program.
Galena also announced the debut of Abstral's sales and marketing campaign at
the PAINWeek conference taking place September 4-7, 2013 in Las Vegas,
NV. With over 1,800 attendees, PAINWeek is one of the nation's largest pain
conferences for healthcare professionals with an interest in pain
management. Galena's commercial team is now fully staffed and on schedule for
a fourth quarter launch with senior level executives and a highly experienced
sales force. The Company's patient assistance and reimbursement program has
been implemented and is being accessed by patients across the country.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in